TY - JOUR
T1 - Presenting features of neuroblastoma with spinal canal invasion. A prospective study of the International Society of Pediatric Oncology Europe - Neuroblastoma (SIOPEN)
AU - Sorrentino, Stefania
AU - Ash, Shifra
AU - Haupt, Riccardo
AU - Plantaz, Dominique
AU - Schiff, Isabelle
AU - Hero, Barbara
AU - Simon, Thorsten
AU - Kachanov, Denis
AU - Shamanskaya, Tatyana
AU - Kraal, Katheljine
AU - Littooij, Annemieke
AU - Wieczoreck, Alexsandra
AU - Balwierz, Walentyna
AU - Laureys, Geneviève
AU - Trager, Catherine
AU - Sertorio, Fiammetta
AU - Erminio, Giovanni
AU - Fragola, Martina
AU - Beck Popovic, Maja
AU - De Bernardi, Bruno
AU - Trahair, Toby
N1 - Funding Information:
This study was partially supported by the Italian Ministry of Health, Ricerca Corrente 2022, no grant applicable, Fondazione Italiana per la lotta al Neuroblastoma, and Children's Cancer Foundation: Project 305: SIOPEN Neuroblastoma Clinical Trials in Australia and New Zealand.
Publisher Copyright:
Copyright © 2022 Sorrentino, Ash, Haupt, Plantaz, Schiff, Hero, Simon, Kachanov, Shamanskaya, Kraal, Littooij, Wieczoreck, Balwierz, Laureys, Trager, Sertorio, Erminio, Fragola, Beck Popovic, De Bernardi and Trahair.
Copyright © 2022 Sorrentino, Ash, Haupt, Plantaz, Schiff, Hero, Simon, Kachanov, Shamanskaya, Kraal, Littooij, Wieczoreck, Balwierz, Laureys, Trager, Sertorio, Erminio, Fragola, Beck Popovic, De Bernardi and Trahair.
PY - 2022/10/10
Y1 - 2022/10/10
N2 - Introduction: Between 5 and 15% of children with neuroblastoma (NB) present with or develop spinal canal invasion (SCI). The majority of these children have symptoms of epidural compression of spinal cord and/or spinal nerves. Treatment of NB-SCI is considered an emergency but its modalities are not yet well-established. Independently of treatment, NB-SCI may result in significant long-term disabilities. We report on the first prospective study of NB-SCI focused on presenting characteristics of both symptomatic and asymptomatic patients and correlation between SCI-related symptoms and imaging features. Materials and methods: This SIOPEN prospective NB-SCI study opened in June 2014. Patient data including SCI symptoms evaluated by standardized measures and spinal cord imaging studies were collected for each patient. For the purpose of this study data entry was locked on July 2021. Results: Of the 208 NB-SCI patients registered, 196 were evaluable for this analysis of whom 67% were symptomatic and 33% asymptomatic. Median age was 11 months. The thorax was the commonest primary tumor site. The median intervals between initial symptoms and diagnosis and between first medical visit and diagnosis were 14 and 3 days, respectively. The was no statistical difference in frequency of presenting characteristics between symptomatic and asymptomatic patients. Presenting features of NB-SCI patients differed from other NBs for older median age, prevalence of thoracic vs. abdominal primary site, prevalence of localized vs. metastatic disease and lower incidence of MYCN gene amplification. The most common SCI features were motor deficit in the younger and pain in the older patients that correlated on imaging with both transverse and longitudinal extent but not with the level of intraspinal tumor. Spinal cord T2-hyperintensity was more frequently detected in symptomatic patients (not significant). Conclusion: This prospective study confirms that children with NB-SCI differ from NBs without SCI. Compared to previous studies, it provides more detailed information regarding presenting symptoms, time intervals between SCI symptoms, medical visit and diagnosis, and correlations between symptoms and imaging features.
AB - Introduction: Between 5 and 15% of children with neuroblastoma (NB) present with or develop spinal canal invasion (SCI). The majority of these children have symptoms of epidural compression of spinal cord and/or spinal nerves. Treatment of NB-SCI is considered an emergency but its modalities are not yet well-established. Independently of treatment, NB-SCI may result in significant long-term disabilities. We report on the first prospective study of NB-SCI focused on presenting characteristics of both symptomatic and asymptomatic patients and correlation between SCI-related symptoms and imaging features. Materials and methods: This SIOPEN prospective NB-SCI study opened in June 2014. Patient data including SCI symptoms evaluated by standardized measures and spinal cord imaging studies were collected for each patient. For the purpose of this study data entry was locked on July 2021. Results: Of the 208 NB-SCI patients registered, 196 were evaluable for this analysis of whom 67% were symptomatic and 33% asymptomatic. Median age was 11 months. The thorax was the commonest primary tumor site. The median intervals between initial symptoms and diagnosis and between first medical visit and diagnosis were 14 and 3 days, respectively. The was no statistical difference in frequency of presenting characteristics between symptomatic and asymptomatic patients. Presenting features of NB-SCI patients differed from other NBs for older median age, prevalence of thoracic vs. abdominal primary site, prevalence of localized vs. metastatic disease and lower incidence of MYCN gene amplification. The most common SCI features were motor deficit in the younger and pain in the older patients that correlated on imaging with both transverse and longitudinal extent but not with the level of intraspinal tumor. Spinal cord T2-hyperintensity was more frequently detected in symptomatic patients (not significant). Conclusion: This prospective study confirms that children with NB-SCI differ from NBs without SCI. Compared to previous studies, it provides more detailed information regarding presenting symptoms, time intervals between SCI symptoms, medical visit and diagnosis, and correlations between symptoms and imaging features.
KW - epidural spinal cord compression
KW - long-term disabilities
KW - neuroblastoma
KW - pediatric tumors
KW - spinal canal invasion
UR - http://www.scopus.com/inward/record.url?scp=85140300227&partnerID=8YFLogxK
U2 - 10.3389/fped.2022.1023498
DO - 10.3389/fped.2022.1023498
M3 - Article
C2 - 36299690
AN - SCOPUS:85140300227
SN - 2296-2360
VL - 10
JO - Frontiers in Pediatrics
JF - Frontiers in Pediatrics
M1 - 1023498
ER -